Rebecca Aft is an American surgical oncologist and breast cancer researcher. Holds the inaugural title of Moley Professor of Endocrine and Oncologic Surgery[1] at Washington University School of Medicine in St. Louis. Aft studies the mechanisms of breast cancer metastasis and explores potential targets for treatment. Her work has identified the anti-metastatic effects of bisphosphonates in patients with breast cancer.
Rebecca Aft | |
|---|---|
| Born | St. Louis, Missouri |
| Alma mater | University of Wisconsin Madison Washington University School of Medicine |
| Known for | Disseminated cancer cells, bisphosphonates, breast cancer |
| Awards | Jeffrey F. Moley Professor of Endocrine and Oncologic Surgery |
| Scientific career | |
| Fields | Breast oncology, general surgery |
| Institutions | Washington University in St. Louis |
Early life and education
editAft was born in St. Louis, Missouri.[2] She left St. Louis to pursue a PhD in biochemistry at the University of Wisconsin–Madison.[2] During her graduate education, she conducted oncology research[3] at the McArdle Laboratory for Cancer Research.[4] Following the completion of her PhD in 1983, Aft completed post-doctoral studies at the Weizmann Institute of Science in Israel.[2] She returned to her hometown of St. Louis in 1987 for a professorship position at Saint Louis University.[2] Shortly after returning to St. Louis, Aft began medical school at Washington University in St. Louis as she wanted experience caring for and treating patients with cancer.[2] She graduated medical school in 1992 and pursued a general surgery residency at Washington University in St. Louis.[3] From 1995 to 1996, Aft held a position of senior registrar at the University of Sydney in Australia, after which she returned to Washington University School of Medicine to complete her chief year as a surgical resident.[3]
Career and research
editIn 1997, Aft accepted a faculty position as a breast surgeon and cancer researcher at Washington University School of Medicine in St. Louis.[5] Aft is a full Professor of Surgery in the Division of General Surgery and Section of Surgical Oncology at Washington University School of Medicine in St. Louis.[6] Aft also operates at the John Cochran Veterans Administration Hospital in St. Louis.[7] She also holds a position on a committee of faculty involved in medical student admissions at Washington University School of Medicine.[7]
Bisphosphonates and breast cancer metastasis
In addition to her roles as a surgeon who operates on patients with breast cancer, Aft leads a laboratory at Washington University School of Medicine with a focus on identifying mechanisms of breast cancer metastasis.[8][2] Her group has focused on the potential of targeting bone turnover in breast cancer patients to prevent metastasis.[9] In a randomized controlled trial published in the Lancet in 2010[10] that women who take bisphosphonates during chemotherapy treatment have less disseminated tumor cells (DCTs) in their bone marrow. In women with triple negative breast cancer, patients who took bisphosphopnates after treatment were less likely to have metastasis (cite, cite).
Robotic-assisted nipple-sparing mastectomies
Aft is also part of a multi-institutional research effort to explore the possibility of minimally invasive and nipple sparing breast surgery on patients with breast cancer.[11] Along with 8 other institutions, Aft leads the Washington University School of Medicine effort to conduct a randomized controlled trial of mastectomies with and without a robot.[9]
Honors and awards
editSelect publications
editWatson MA, Ylagan LR, Trinkaus KM, Gillanders WE, Naughton MJ, Weilbaecher KN, Fleming TP, Aft RL. Isolation and molecular profiling of bone marrow micrometastases identifies TWIST1 as a marker of early tumor relapse in breast cancer patients. Clin Cancer Res. 2007 Sep 1;13(17):5001-9. doi: 10.1158/1078-0432.CCR-07-0024. PMID 17785550; PMCID: PMC2680916.[14]
Aft R, Naughton M, Trinkaus K, Watson M, Ylagan L, Chavez-MacGregor M, Zhai J, Kuo S, Shannon W, Diemer K, Herrmann V, Dietz J, Ali A, Ellis M, Weiss P, Eberlein T, Ma C, Fracasso PM, Zoberi I, Taylor M, Gillanders W, Pluard T, Mortimer J, Weilbaecher K. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol. 2010 May;11(5):421-8. doi: 10.1016/S1470-2045(10)70054-1. Epub 2010 Mar 31. PMID 20362507; PMCID: PMC3792651.[10]
Aft RL, Naughton M, Trinkaus K, Weilbaecher K. Effect of (Neo)adjuvant zoledronic acid on disease-free and overall survival in clinical stage II/III breast cancer. Br J Cancer. 2012 Jun 26;107(1):7-11. doi: 10.1038/bjc.2012.210. Epub 2012 May 22. PMID 22617128; PMCID: PMC3389411.[15]
Jallouk AP, Paravastu S, Weilbaecher K, Aft RL. Long-term outcome of (neo)adjuvant zoledronic acid therapy in locally advanced breast cancer. Breast Cancer Res Treat. 2021 May;187(1):135-144. doi: 10.1007/s10549-021-06100-2. Epub 2021 Feb 16. PMID 33591469; PMCID: PMC8068643.[16]
References
edit- ^ "Aft Installed as Inaugural Jeffrey F. Moley Professor of Endocrine and Oncologic Surgery | Department of Surgery | Washington University in St. Louis". surgery.wustl.edu. Retrieved 2023-11-30.
- ^ a b c d e f g Corrigan, Patricia (2011-05-22). "Dr. Rebecca Aft". St. Louis Jewish Light. Retrieved 2023-11-30.
- ^ a b c "Rebecca Aft, MD, PhD". Siteman Cancer. Retrieved November 30, 2023.
- ^ "Rebecca Aft". www.intechopen.com. Retrieved 2023-11-30.
- ^ Sauerwein, Kristina (2023-07-27). "Aft named inaugural Moley Professor of Endocrine and Oncologic Surgery". Washington University School of Medicine in St. Louis. Retrieved 2023-11-30.
- ^ "Rebecca L. Aft, MD, PhD". Washington University Physicians. Retrieved 2023-11-30.
- ^ a b "Rebecca Aft, MD, PhD | Medical Student Admissions | Washington University in St. Louis". mdadmissions.wustl.edu. Retrieved 2023-11-30.
- ^ "Angle PLC Announces Potential to Prevent Breast Cancer Relapse". Bloomberg.com. 2021-06-01. Retrieved 2023-11-30.
- ^ a b "Dr. Aft on Bisphosphonates for Breast Cancer". OncLive. 2013-09-18. Retrieved 2023-11-30.
- ^ a b Aft, Rebecca; Naughton, Michael; Trinkaus, Kathryn; Watson, Mark; Ylagan, Lourdes; Chavez-MacGregor, Mariana; Zhai, Jing; Kuo, Sacha; Shannon, William; Diemer, Kathryn; Herrmann, Virginia; Dietz, Jill; Ali, Amjad; Ellis, Matthew; Weiss, Peter (May 2010). "Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial". The Lancet. Oncology. 11 (5): 421–428. doi:10.1016/S1470-2045(10)70054-1. ISSN 1474-5488. PMC 3792651. PMID 20362507.
- ^ "FORCE | Nipple Sparing Mastectomy With Immediate Implant-Based Reconstruction for Women With Early-Stage Breast Cancer". FORCE | Nipple Sparing Mastectomy With Immediate Implant-Based Reconstruction for Women With Early-Stage Breast Cancer. Retrieved 2023-11-30.
- ^ Palmer, Jordan (2023-09-10). "Dr. Rebecca Aft named to prestigous new professorship". St. Louis Jewish Light. Retrieved 2023-11-30.
- ^ "Women in Surgery then and now" (PDF). Association of Women Surgeons (AWS). 2002. Retrieved November 30, 2023.
- ^ Watson, Mark A.; Ylagan, Lourdes R.; Trinkaus, Kathryn M.; Gillanders, William E.; Naughton, Michael J.; Weilbaecher, Katherine N.; Fleming, Timothy P.; Aft, Rebecca L. (2007-09-01). "Isolation and molecular profiling of bone marrow micrometastases identifies TWIST1 as a marker of early tumor relapse in breast cancer patients". Clinical Cancer Research. 13 (17): 5001–5009. doi:10.1158/1078-0432.CCR-07-0024. ISSN 1078-0432. PMC 2680916. PMID 17785550.
- ^ Aft, R. L.; Naughton, M.; Trinkaus, K.; Weilbaecher, K. (June 2012). "Effect of (Neo)adjuvant zoledronic acid on disease-free and overall survival in clinical stage II/III breast cancer". British Journal of Cancer. 107 (1): 7–11. doi:10.1038/bjc.2012.210. ISSN 1532-1827. PMC 3389411. PMID 22617128.
- ^ Jallouk, Andrew P.; Paravastu, Sriram; Weilbaecher, Katherine; Aft, Rebecca L. (May 2021). "Long-term outcome of (neo)adjuvant zoledronic acid therapy in locally advanced breast cancer". Breast Cancer Research and Treatment. 187 (1): 135–144. doi:10.1007/s10549-021-06100-2. ISSN 1573-7217. PMC 8068643. PMID 33591469.